Comparison of the Hydrolysis and Esterification Methods for the Determination of Genotoxic 5-Chlorothiophene-2-Carbonyl Chloride in Rivaroxaban Using HPLC

This paper describes the development and comparison of the hydrolysis and esterification methods for the determination of 5-chlorothiophene-2-carbonylchloride (CTCC), a potential genotoxic impurity, in the drug rivaroxaban (RIVA) drug substance. Poor recovery of CTCC in the hydrolysis method occurred due to the high percentage of acetonitrile, which suppressed the hydrolysis reaction, but was solved by adding Na2CO3. In the esterification approach, the problem of poor recovery was also encountered because of the competition between the hydrolysis and esterification reactions, and a stable recovery of CTCC under different water content conditions was obtained by adding glacial acetic acid. A high-performance liquid chromatography (HPLC) method was developed to separate the hydrolysis product, 5-chlorothiophene-2-carboxylic acid (CTCA), and the esterification product, methyl-5-chlorothiophene-2-carboxylate (MCTC), from RIVA, process-related impurities and degradation products of RIVA. Standard curves were linear (r = 0.9999) for the hydrolysis and esterification methods in the ranges of 16.7–280.3 ppm and 15.3–255.0 ppm, respectively, and limit of quantitation (LOQ) of CTCA and MCTC was 16.7 and 15.3 ppm, respectively. The accuracy (% recovery) was 98.08–100.5 % for the hydrolysis method and 97.86–99.05 % for the esterification method. Both methods had good repeatability and stability. During the real sample analysis, it was found that the hydrolysis method could not differentiate CTCC and the inherent CTCA impurity, leading to overestimation of residual CTCC in the RIVA. The esterification method was a better solution for the accurate measurement of residual CTCC in RIVA.

[1]  David Q. Liu,et al.  Recent advances in trace analysis of pharmaceutical genotoxic impurities. , 2010, Journal of pharmaceutical and biomedical analysis.

[2]  Nanduri V V S S Raman,et al.  Sensitive derivatization methods for the determination of genotoxic impurities in drug substances using hyphenated techniques. , 2014, Journal of pharmaceutical and biomedical analysis.

[3]  S. Magiera Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPS-UHPLC-MS/MS for therapeutic drug monitoring. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  R. Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.

[5]  Jun Wang,et al.  Ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry method development and validation for determining genotoxic 2,5-dichlorobenzoyl chloride in MLN9708 drug substance. , 2014, Journal of pharmaceutical and biomedical analysis.

[6]  K Jayasree,et al.  A validated CE method for determining dimethylsulfate a carcinogen and chloroacetyl chloride a potential genotoxin at trace levels in drug substances. , 2012, Journal of pharmaceutical and biomedical analysis.

[7]  M. Iqbal,et al.  A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample , 2014, Journal of Thrombosis and Thrombolysis.

[8]  J. Hulot,et al.  Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2014, Journal of pharmaceutical and biomedical analysis.

[9]  A. Turpie Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation , 2014, Therapeutics and clinical risk management.

[10]  Scott A. Miller,et al.  Development and validation of a specific and sensitive GC-FID method for the determination of impurities in 5-chlorovaleroyl chloride. , 2010, Journal of pharmaceutical and biomedical analysis.

[11]  G. Rohde Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  Ramakrishna Kuntamukkala,et al.  Development and validation of a stability indicating LC-PDA-MS/MS method for separation, identification and characterization of process related and stress degradation products of rivaroxaban , 2014 .